Bristol Myers Squibb社は第3相EXCALIBER-RRMM試験の結果を発表した。iberdomide＋ダラツムマブ併用療法は、対照群に比べMRD陰性完全奏効率を約2倍に高めた（41.1％対20.7％）。

FDA granted accelerated approval to iberdomide (Zenbexus) in combination with daratumumab and hyaluronidase-fihj and dex

FDA granted accelerated approval to iberdomide (Zenbexus) in combination with daratumumab and hyaluronidase-fihj and dex

Discover the world’s best science and medicine | Nature.com

“We continue to be encouraged by the sustained progress being made in myeloma research and remain hopeful that advances like this will lead to better outcomes for patients and families," said Lore Gru...

On August 13, 2026, the Food and Drug Administration granted accelerated approval to iberdomide (Zenbexus, Bristol-Myers Squibb Company) in combination with daratumumab and hyaluronidase-fihj and dexa...

The clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise.

Hematogenix's MM MRD assay has played a crucial role in the FDA's accelerated approval of ZENBEXUS, the first CELMoD therapy for multiple myeloma.

Hematogenix's proprietary Multiple Myeloma MRD (MM MRD) assay measured the primary efficacy endpoint cited in the FDA-approval of ZENBEXUS (iberdomide), reinforcing Hematogenix's role as a specialized global leader in registrational oncology trials. TINLEY PARK, Ill., Aug. 19, 2026...

The FDA has given accelerated approval to iberdomide (Zenbexus) in combination with daratumumab and dexamethasone for adults with multiple myeloma that has returned or is resistant to previous treatme

The U.S. FDA has granted accelerated approval to Zenbexus (iberdomide) in combination with daratumumab and hyaluronidase-fihj plus dexamethasone for adults with multiple myeloma who have undergone at

Today, we’re looking at a new multiple myeloma approval for Bristol Myers Squibb, PBMs embracing TrumpRx price comparisons, and Novartis winning a key U.K. patent fight over Entresto. My son built a structurally sound bridge yesterday out of latticed twigs; it supported my weight and also his. It was a moment of great pride. Hire him, he’s 8. Bristol’s Zenbexus wins accelerated approval in multiple myeloma…

FDA granted accelerated approval to iberdomide (Zenbexus) in combination with daratumumab and hyaluronidase-fihj and dex

Bristol Myers Squibb’s Zenbexus is the first FDA-approved drug in a new class of cancer drugs called CELMoDs. The pharma company is positioning this molecule as a successor to its legacy products for ...

Hematogenix's proprietary Multiple Myeloma MRD (MM MRD) assay measured the primary efficacy endpoint cited in the FDA-approval of ZENBEXUS (iberdomide), reinforcing Hematogenix's role as a specialized global leader in registrational oncology trials. TINLEY PARK, Ill., Aug. 14, 2026...

Learn about the FDA approval of iberdomide plus daratumumab and hyaluronidase-fihj and dexamethasone for treating multiple myeloma, offering new hope for patients with relapsed or refractory disease.

Bristol Myers Squibb’s Zenbexus is the first FDA-approved drug in a new class of cancer drugs called CELMoDs. The pharma company is positioning this molecule as a successor to its legacy products for multiple myeloma. The post Bristol Myers Squibb Protein Degrader Wins First-in-Class FDA Nod in Multiple Myeloma appeared first on MedCity News .

Bristol's Zenbexus wins accelerated approval, Novartis wins UK patent fight over Entresto, and more biotech news from The Readout

The US Food and Drug Administration has granted accelerated approval to iberdomide (Zenbexus) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma…

Accelerated FDA approval of the first-in-class CELMoD agent iberdomide (Zenbexus) offers a new oral option for adults with relapsed or refractory multiple myeloma.